Navilyst Medical offers an enhanced PICC Convenience Kitting and a new Xcela Power Injectable Port catheter provide a means for long-term delivery of fluids and medications including chemotherapy, and a new EZ Huber Safety Infusion Set offers a dual-action safety mechanism designed to reduce the risk of bloodborne pathogen exposure.
October 31, 2008 - TCT India Live is a three-day symposium designed for interventional cardiologists, clinical ...
There is considerable interest in being able to clearly identify vulnerable plaque (VP) and research efforts are intensifying. Several invasive imaging technologies claim to detect VP, and while the link between VP identification, plaque rupture and clinical events has yet to be firmly established, progress is being made in the research.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
GE Healthcare’s recently released Vivid E9 ultrasound features Accelerated Volume Architecture (AVA), which not only makes single beat acquisition possible but, working alongside Extended Signal transducer technology in each probe, it reportedly delivers a leap in 2D, 4D and shared service image quality across the entire patient population.
Micrus Endovascular Corp. initiated its worldwide launch of Neuropath guide catheter line, designed with a highly flexible and visible tip so neurointerventionalists can gain better vessel access and greater vessel selection in treating patients with complex anatomies.
CardioECG 3.2, introduced by LUMEDX Corp. and Epiphany Cardiography Products, is a multimodality, multivendor, pure-Web ...
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
A new ultrasound system for radiology and vascular applications, the LOGIQ E9, fuses ultrasound images with images from other imaging modalities like CT and MR.
The nSPEED reconstruction software from Digirad Corp. is for use in its imaging systems for SPECT procedures at either half-time and/or half count densities with parallel and nonparallel hole collimators, reportedly resulting in quicker exams, improved image quality and less radiation exposure.
The FDA granted approval for Covidien’s generic kit for the preparation of technetium Tc99m Sestamibi injection use for nuclear myocardial perfusion imaging.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Just ahead of the expected release of clinical practice guidelines on Familial Hypercholesterolaemia (FH) by the influential National Institute for Clinical Excellence (NICE), Tepnel Life Sciences PLC launched a DNA test for the early detection of FH, a genetic condition that predisposes individuals to high blood cholesterol levels and increased risk of cardiovascular disease.
October 31, 2008 - Surface modification and drug delivery technologies company SurModics Inc. said today it is providing ...
"Potential” can be a loaded word, especially in healthcare. Many clinicians have tagged coronary MR angiography (MRA) with the “potential” label. Despite the scan’s reported safety advantages over coronary CT angiography (CTA), as well as its superior physiologic information, coronary MRA has not gained the widespread acceptance of coronary CTA.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Stereotaxis Inc. said the FDA cleared its magnetically tipped PowerAssert radiofrequency (RF) guide wire to cross chronic total occlusions (CTOs) in the peripheral vasculature.
Boston Scientific's TAXUS Express2 Atom paclitaxel-eluting coronary stent system is a drug-eluting stent (DES) specifically designed for treating small coronary vessels. The TAXUS Express2 Atom Stent System is the only DES approved by the FDA for use in vessels as small as 2.25 mm in diameter, Boston Scientific said. The Taxus Express 2 Atom received FDA approval in the fall of 2008.
October 31, 2008 - Corgenix Medical Corp. recently said new CHARISMA trial findings published in Circulation confirm ...